IDEAYA Biosciences, Inc. (IDYA)
After hours:
| Previous close | 41.49 |
| Open | 42.27 |
| Bid | 42.12 x 300 |
| Ask | 42.20 x 300 |
| Day's range | 42.00 - 43.00 |
| 52-week range | 18.96 - 47.74 |
| Volume | |
| Avg. volume | 714,354 |
| Market cap | 3.154B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.00 |
PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
- PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (
- PR Newswire
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinoi
